Highlights
- Ravulizumab, a long-acting terminal complement C5 inhibitor, significantly reduces proteinuria in IgA nephropathy patients compared to placebo.
- Phase 3 interim analysis showed a 43.4% adjusted reduction in 24-hour urinary protein-to-creatinine ratio at 34 weeks.
- Complement activation and renal inflammation biomarkers markedly decreased with ravulizumab treatment, supporting mechanism of action.
- Ravulizumab demonstrated a favorable safety profile with fewer serious adverse events than placebo and no meningococcal infections.
Background
